CIPRO TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE)

제공처:

BAYER INC

ATC 코드:

J01MA02

INN (International Name):

CIPROFLOXACIN

복용량:

750MG

약제 형태:

TABLET

구성:

CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 750MG

관리 경로:

ORAL

패키지 단위:

50/100

처방전 유형:

Prescription

치료 영역:

QUINOLONES

제품 요약:

Active ingredient group (AIG) number: 0123207002; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2018-12-10

제품 특성 요약

_CIPRO_
_®_
_ and CIPRO_
®
_ ORAL SUSPENSION_
Page 1 of 58
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CIPRO
®
(Ciprofloxacin tablet USP)
250 mg, 500 mg, 750 mg
PR
CIPRO
® ORAL SUSPENSION
(Ciprofloxacin oral suspension)
10 g/100 mL
Antibacterial Agent
Manufactured by:
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Revision:
February 18, 2020
Submission Control No: 233351
© 2020, Bayer Inc.
® TM see www.bayer.ca/tm-mc
All other trademarks are the property of their respective owners.
_CIPRO_
_®_
_ and CIPRO_
®
_ ORAL SUSPENSION_
Page 2 of 58
TABLE OF CONTENTS
PART
I:
HEALTH
PROFESSIONAL
INFORMATION ..........................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
7
WARNINGS AND PRECAUTIONS
.............................................................................................
8
ADVERSE REACTIONS
.............................................................................................................
14
DRUG INTERACTIONS
.............................................................................................................
17
DOSAGE AND ADMINISTRATION
.........................................................................................
22
OVERDOSAGE
...........................................................................................................................
25
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
26
STORAGE AND STABILITY
.....................................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................